Single-domain antibodies for biomedical applications

被引:56
作者
Krah, Simon [1 ]
Schroeter, Christian [1 ]
Zielonka, Stefan [2 ]
Empting, Martin [3 ]
Valldorf, Bernhard [2 ]
Kolmar, Harald [2 ]
机构
[1] Merck KGaA, Merck Serono, Prot Engn & Antibody Technol, Darmstadt, Germany
[2] Tech Univ Darmstadt, Inst Organ Chem & Biochem, Alarich Weiss Str 4, D-64287 Darmstadt, Germany
[3] Univ Saarland, Helmholtz Inst Pharmaceut Res Saarland HIPS, Dept Drug Design & Optimizat, D-66123 Saarbrucken, Germany
关键词
VHH; heavy chain antibody; Antibody engineering; antibody fragment; single chain binding domain; IgNAR; SHARK IGNAR ANTIBODY; ANTIGEN RECEPTOR IGNAR; VARIABLE DOMAINS; BIOPHYSICAL PROPERTIES; AFFINITY MATURATION; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; SELECTION; FRAGMENTS; NANOBODY;
D O I
10.3109/08923973.2015.1102934
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Single-domain antibodies are the smallest antigen-binding units of antibodies, consisting either only of one variable domain or one engineered constant domain that solely facilitates target binding. This class of antibody derivatives comprises naturally occurring variable domains derived from camelids and sharks as well as engineered human variable or constant antibody domains of the heavy or light chain. Because of their high affinity and specificity as well as stability, small size and benefit of multiple re-formatting opportunities, those molecules emerged as promising candidates for biomedical applications and some of these entities have already proven to be successful in clinical development.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 114 条
[1]   What's fueling the biotech engine-2010 to 2011 [J].
Aggarwal, Saurabh .
NATURE BIOTECHNOLOGY, 2011, 29 (12) :1083-1089
[2]   What's fueling the biotech engine-2011 to 2012 [J].
Aggarwal, Saurabh .
NATURE BIOTECHNOLOGY, 2012, 30 (12) :1191-1197
[3]  
Arbabi-Ghahroudi M, 2010, METHODS MOL BIOL, V634, P309, DOI 10.1007/978-1-60761-652-8_22
[4]  
Arbabi-Ghahroudi Mehdi, 2009, V502, P341, DOI 10.1007/978-1-60327-565-1_20
[5]  
Barelle C, 2009, ADV EXP MED BIOL, V655, P49, DOI 10.1007/978-1-4419-1132-2_6
[6]   Immunogenicity, efficacy and adverse events of adalimumab in RA patients [J].
Bender, Niko K. ;
Heilig, Christoph E. ;
Droell, Benjamin ;
Wohlgemuth, Jessica ;
Armbruster, Franz-Paul ;
Heilig, Bernhard .
RHEUMATOLOGY INTERNATIONAL, 2007, 27 (03) :269-274
[7]   DARPins and other repeat protein scaffolds: advances in engineering and applications [J].
Boersma, Ykelien L. ;
Plueckthun, Andreas .
CURRENT OPINION IN BIOTECHNOLOGY, 2011, 22 (06) :849-857
[8]   Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock [J].
Bojalil, Rafael ;
Teresa Mata-Gonzalez, Maria ;
Sanchez-Munoz, Fausto ;
Yee, Yepci ;
Argueta, Ivan ;
Bolanos, Lucia ;
Manuel Amezcua-Guerra, Luis ;
Amanda Camacho-Villegas, Tanya ;
Sanchez-Castrejon, Edna ;
Jakob Garcia-Ubbelohde, Walter ;
Fedorovish Licea-Navarro, Alexei ;
Marquez-Velasco, Ricardo ;
Fernando Paniagua-Solis, Jorge .
BMC IMMUNOLOGY, 2013, 14
[9]   Antibody-drug conjugates-A new wave of cancer drugs [J].
Bouchard, Herve ;
Viskov, Christian ;
Garcia-Echeverria, Carlos .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (23) :5357-5363
[10]   Monoclonal antibody therapeutics: history and future [J].
Buss, Nicholas A. P. S. ;
Henderson, Simon J. ;
McFarlane, Mary ;
Shenton, Jacintha M. ;
de Haan, Lolke .
CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (05) :615-622